CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 474 enrolled
Drug / intervention
ABT-143 +1 moredrug
Likely dose
simvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00812955
NCT00812955Phase 3Completed
CompareCT.gov

An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia

AstraZeneca·interventional·Posted Dec 22, 2008·Updated Oct 3, 2012

In Brief

A Phase 3 clinical trial evaluating ABT-143 and simvastatin for Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia. Completed, enrolled 474 participants across 129 sites.

Detailed Summary

The primary purpose of this study is to test the effect and safety of three different doses of ABT-143 compared to simvastatin in subjects with elevated levels of low density lipoprotein cholesterol ("bad cholesterol") and triglycerides.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 22, 2008
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.5 years ago

Interventions

ABT-143drug

Once daily for 8 weeks

simvastatindrug

Once daily for 8 weeks simvastatin capsules 40 mg